ANOC 001
Alternative Names: ANOC-001; KRAS-G12V targeting TCR-T cell therapyLatest Information Update: 03 Feb 2025
Price :
$50 *
At a glance
- Originator Anocca
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 26 Nov 2024 Anocca files Clinical Trial Application with the European Medicines Agency for Adenocarcinoma
- 26 Nov 2024 Anocca plans a phase I/II VIDAR-1 multi-asset umbrella trial for ANOC 001 in Adenocarcinoma (Late-stage disease) (Parenteral) in the second quarter of 2025
- 13 Sep 2024 Pharmacodynamics data from a preclinical study in Cancer presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)